Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-03-08 Sale | 2023-03-10 6:10 pm | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP, GM of U.S., Commercial Ma | 3,013 | $139.74 | $421,043 | 30,560 (Direct) | View |
| 2022-06-06 Sale | 2022-06-08 4:56 pm | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP & GM, North America | 3,829 | $151.45 | $579,898 | 24,754 (Direct) | View |
| 2021-11-11 Sale | 2021-11-15 7:30 pm | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP & GM, North America | 2,748 | $135.01 | $371,000 | 21,135 (Direct) | View |
| 2020-03-18 Sale | 2020-03-19 4:32 pm | Myovant Sciences Ltd. | MYOV | Sablich Kim Chief Commercial Officer | 785 | $7.3714 | $5,787 | 58,905 (Direct) | View |
| 2020-01-15 Sale | 2020-01-16 5:28 pm | Myovant Sciences Ltd. | MYOV | Sablich Kim Chief Commercial Officer | 4,840 | $14.04 | $67,954 | 59,690 (Direct) | View |
| 2019-12-18 Sale | 2019-12-19 4:25 pm | Myovant Sciences Ltd. | MYOV | Sablich Kim Chief Commercial Officer | 2,585 | $16.22 | $41,929 | 64,530 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-06-05 Disposition | 2023-06-07 7:15 pm | N/A N/A | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP, GM of U.S. | 2,082 | $129.73 | 28,478 (Direct) | View |
| 2023-03-05 Tax Withholding | 2023-03-07 8:50 pm | N/A N/A | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP, GM of U.S., Commercial Ma | 1,610 | $142.78 | 33,573 (Direct) | View |
| 2023-03-03 Option Award | 2023-03-07 8:50 pm | N/A N/A | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP, GM of U.S., Commercial Ma | 10,429 | $0 | 33,573 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 8:50 pm | N/A 2033-02-28 | Eiger BioPharmaceuticals Inc. | EIGR | Sablich Kim Director | 28,000 | $0 | 28,000 (Direct) | View |
| 2022-06-06 Tax Withholding | 2022-06-08 4:56 pm | N/A N/A | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP & GM, North America | 1,759 | $149.25 | 24,754 (Direct) | View |
| 2022-03-11 Option Award | 2022-03-11 9:06 pm | N/A 2032-03-10 | Eiger BioPharmaceuticals Inc. | EIGR | Sablich Kim Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-09 6:05 pm | N/A N/A | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP & GM, North America | 9,953 | $0 | 30,342 (Direct) | View |
| 2022-03-05 Tax Withholding | 2022-03-09 6:05 pm | N/A N/A | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP & GM, North America | 746 | $153.96 | 30,342 (Direct) | View |
| 2021-06-05 Tax Withholding | 2021-06-09 6:55 pm | N/A N/A | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP & GM, North America | 1,452 | $176.47 | 23,883 (Direct) | View |
| 2021-04-23 Option Award | 2021-04-23 5:35 pm | N/A 2031-04-22 | Eiger BioPharmaceuticals Inc. | EIGR | Sablich Kim Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2021-02-25 Option Award | 2021-03-01 6:17 pm | N/A N/A | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP & GM, North America | 8,535 | $0 | 25,335 (Direct) | View |
| 2020-08-06 Option Award | 2020-08-07 7:26 pm | N/A 2030-08-05 | Jazz Pharmaceuticals plc | JAZZ | Sablich Kim EVP & GM, North America | 58,800 | $0 | 58,800 (Direct) | View |
| 2020-04-03 Option Award | 2020-04-07 5:14 pm | N/A 2030-04-02 | Myovant Sciences Ltd. | MYOV | Sablich Kim Chief Commercial Officer | 222,269 | $0 | 281,174 (Direct) | View |
| 2019-08-26 Disposition | 2019-08-27 4:59 pm | N/A 2028-12-16 | Myovant Sciences Ltd. | MYOV | Sablich Kim Chief Commercial Officer | 199,630 | $0 | 266,745 (Direct) | View |
| 2019-08-26 Option Award | 2019-08-27 4:59 pm | N/A 2028-12-16 | Myovant Sciences Ltd. | MYOV | Sablich Kim Chief Commercial Officer | 237,045 | $0 | 266,745 (Direct) | View |